Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,007 stopped studies mapped to B-Cell Non-Hodgkin Lymphoma and descendants · 89% state a reason
Over the 1,007 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02008006 | BENdamustine at Elevated Dose for Relapsed Follicular Lymphoma in Intensification Therapy…(BENEFIT) | Phase 2 | terminated | Dec 11, 2013 | Centre Leon Berard | Insufficient recruitment and unavailability of the treatment | Enrollment / accrual |
| NCT01479582 | Providing Access to Cord Blood Units for Transplants | Phase 2 | withdrawn | Nov 24, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02454270 | A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory… | Phase 1 | terminated | May 27, 2015 | Janssen Research & Development, LLC | Recent advances in the treatment of B cell malignancies resulting in new treatments being approved… | Other (stated, no rule matched) |
| NCT01470131 | A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or… | Phase 3 | terminated | Nov 11, 2011 | AB Science | Sponsor decision based on portfolio prioritization | Sponsor / business decision |
| NCT03349346 | Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and… | Phase 1 | withdrawn | Nov 21, 2017 | Gilead Sciences | The European Medical Agency granted a Paediatric Investigational Product-specific waiver on the… | Other (stated, no rule matched) |
| NCT01374217 | Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in… | Phase 2 | terminated | Jun 15, 2011 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | early stopping rule | Other (stated, no rule matched) |
| NCT01203930 | A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL | Phase 2 | terminated | Sep 17, 2010 | Gilead Sciences | not stated | Not stated |
| NCT03120000 | PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System… | Phase 2 | withdrawn | Apr 19, 2017 | PIQUR Therapeutics AG | Withdrawn | Other (stated, no rule matched) |
| NCT02538926 | Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin… | Phase 2 | withdrawn | Sep 2, 2015 | University of Washington | Drugs unavailable | Other (stated, no rule matched) |
| NCT02376933 | Vertebral Augmentation and Radiotherapy of Collapse Spinal Metastatic Cancer | N/A | terminated | Mar 3, 2015 | University of Arizona | PI left the department; protocol transfer did not take place. | Investigator |
| NCT00790842 | Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple…(PrE1003) | Phase 1 / Phase 2 | terminated | Nov 14, 2008 | PrECOG, LLC. | Slow enrollment | Enrollment / accrual |
| NCT01676961 | Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving… | Phase 2 | terminated | Aug 31, 2012 | NYU Langone Health | PI left the institution | Investigator |
| NCT02075021 | Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel…(rev/abraxane) | Phase 1 / Phase 2 | terminated | Mar 3, 2014 | NYU Langone Health | PI left the institution | Investigator |
| NCT01672736 | A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed… | Phase 1 / Phase 2 | terminated | Aug 27, 2012 | University Health Network, Toronto | The Sponsor decided to stop further manufacture the study drug 'Linsitinib' in Nov 2015. | Drug supply |
| NCT02462525 | Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed… | Phase 1 | terminated | Jun 4, 2015 | AbbVie | No Go decision for ABBV-838 | Other (stated, no rule matched) |
| NCT03212807 | Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS…(DuRIANS) | Phase 2 | withdrawn | Jul 11, 2017 | Singapore General Hospital | FDA Hold for Combination Studies using Imids and PD1/PDL1 Compounds | Other (stated, no rule matched) |
| NCT02489500 | Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib(VelRand) | Phase 3 | terminated | Jul 3, 2015 | Boston Medical Center | Enrollment held for toxicity evaluation; then closed due to competing trial | Safety / toxicity |
| NCT00918463 | A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With… | Phase 2 | terminated | Jun 11, 2009 | Weill Medical College of Cornell University | The study was terminated early due to lack of accrual. | Enrollment / accrual |
| NCT02228512 | Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated… | Phase 1 / Phase 2 | withdrawn | Aug 29, 2014 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00847223 | Efficacy and Safety of the Farnesyl-transferase Inhibitor (Tipifarnib) in Mantle Cell… | Phase 2 | terminated | Feb 19, 2009 | Lymphoma Study Association | Inefficiency of treatment | Other (stated, no rule matched) |
| NCT02030483 | Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma(PD + RD) | Phase 1 | terminated | Jan 8, 2014 | Weill Medical College of Cornell University | The company providing one of the study drugs withdrew its support due to low enrollment. Therefore,… | Enrollment / accrual |
| NCT02986451 | Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma | Phase 2 | withdrawn | Dec 8, 2016 | Sun Yat-sen University | not stated | Not stated |
| NCT03227432 | An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and… | Phase 2 | withdrawn | Jul 24, 2017 | Dana-Farber Cancer Institute | Withdrawn before enrollment due to issues around the FDA hold on PD-1/PD-L1 drugs in combination… | Enrollment / accrual |
| NCT02702141 | A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma | Phase 1 | terminated | Mar 8, 2016 | Seagen Inc. | not stated | Not stated |
| NCT00012298 | Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and… | Phase 1 / Phase 2 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | Trial completed prematurely. | Other (stated, no rule matched) |
| NCT00124579 | S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or… | Phase 2 | terminated | Jul 28, 2005 | SWOG Cancer Research Network | poor accrual | Enrollment / accrual |
| NCT02720510 | A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible,…(PANORAMA4) | Phase 2 | terminated | Mar 28, 2016 | Novartis Pharmaceuticals | A study was terminated due to low enrollment. | Enrollment / accrual |
| NCT01779167 | Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom…(THRiL for WM) | Phase 2 | terminated | Jan 30, 2013 | Weill Medical College of Cornell University | Slow Accrual | Enrollment / accrual |
| NCT01484626 | Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma(BVRD) | Phase 1 / Phase 2 | terminated | Dec 2, 2011 | Loyola University | Celgene would no longer supply lenalidomide for the study | Drug supply |
| NCT02168907 | CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or… | Phase 1 | terminated | Jun 20, 2014 | Wake Forest University Health Sciences | Slow Accruals | Enrollment / accrual |
| NCT02971410 | Simvastatin in Overcoming Chemotherapy Resistance in Patients With Relapsed or Refractory… | Early Phase 1 | withdrawn | Nov 23, 2016 | Wake Forest University Health Sciences | PI no longer interested in pursuing study. | Other (stated, no rule matched) |
| NCT00664378 | Efficacy Study of CYT997 in Multiple Myeloma | Phase 2 | terminated | Apr 22, 2008 | Gilead Sciences | Difficulty enrolling patients | Enrollment / accrual |
| NCT00538824 | Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed…(DexTR) | Phase 2 | terminated | Oct 3, 2007 | Weill Medical College of Cornell University | low enrollment | Enrollment / accrual |
| NCT01812005 | Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory… | Phase 2 | terminated | Mar 15, 2013 | Ohio State University Comprehensive Cancer Center | Slow patient enrollment and study discontinued after 14 patients enrolled | Enrollment / accrual |
| NCT01979276 | Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma(Romi Poma) | Phase 1 / Phase 2 | terminated | Nov 8, 2013 | Weill Medical College of Cornell University | this study was terminated due to losing financial support, and enrollment challenges | Enrollment / accrual |
| NCT02420210 | Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell… | Phase 2 | terminated | Apr 17, 2015 | University of Chicago | Trials was stopped early due to lack of funding. | Funding |
| NCT01174082 | Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma… | Phase 2 | terminated | Aug 3, 2010 | M.D. Anderson Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT03023527 | Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma | Phase 1 | terminated | Jan 18, 2017 | PETHEMA Foundation | Safety | Safety / toxicity |
| NCT00482053 | Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation… | Phase 2 | terminated | Jun 4, 2007 | Stanford University | Low accrual | Enrollment / accrual |
| NCT02985333 | Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma | Phase 2 | withdrawn | Dec 7, 2016 | Sun Yat-sen University | not stated | Not stated |
| NCT02372240 | A Study of VLX1570 and Dexamethasone in Myeloma Patients | Phase 1 / Phase 2 | terminated | Feb 26, 2015 | Vivolux AB | Dose limiting tox is observed. Study put on full clinical hold. | Other (stated, no rule matched) |
| NCT00290407 | Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic… | Phase 2 | terminated | Feb 13, 2006 | University of Louisville | terminated due to lack of accrual | Enrollment / accrual |
| NCT02877082 | Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood… | Phase 2 | terminated | Aug 24, 2016 | Emory University | not stated | Not stated |
| NCT00626626 | Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation | Phase 1 / Phase 2 | terminated | Feb 29, 2008 | Milton S. Hershey Medical Center | Investigator decision | Investigator |
| NCT01382615 | Protocol to Obtain Blood and Bone Marrow Samples for Myeloma Research | — | terminated | Jun 27, 2011 | Dartmouth-Hitchcock Medical Center | Unable to fill cohort | Other (stated, no rule matched) |
| NCT02155634 | Continuous Lenalidomide Therapy Versus Observation Following Induction Without… | Phase 3 | withdrawn | Jun 4, 2014 | Celgene | The study was terminated due to poor feasibility and lack of interest at the participating sites. | Other (stated, no rule matched) |
| NCT02732925 | To Compare Conservative Management Vs. Balloon Kyphoplasty in the Treatment of VCFs in…(MELODY) | N/A | terminated | Apr 11, 2016 | Royal National Orthopaedic Hospital NHS Trust | Difficulties with recruitment due to change in referral rates. | Enrollment / accrual |
| NCT00909948 | Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following…(RLI) | Phase 1 | terminated | May 29, 2009 | Massachusetts General Hospital | Slow Accrual | Enrollment / accrual |
| NCT02488512 | Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse…(itTRIOlym) | Phase 2 | terminated | Jul 2, 2015 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | critical low recruitment rate | Enrollment / accrual |
| NCT02530125 | Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma… | Phase 2 | terminated | Aug 20, 2015 | Northwestern University | sponsor decided to discontinue development of the study drug. | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jan 8, 2019source: clinicaltrials